Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome

Paola G. Meregalli, Jan M. Ruijter, Nynke Hofman, Connie R. Bezzina, Arthur A M Wilde, Hanno L. Tan

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Introduction: Provocation tests with sodium channel blockers are often required to unmask ECG abnormalities in Brugada syndrome (BrS). However, their diagnostic value is only partially established, while life-threatening ventricular arrhythmias during these tests were reported. We aimed to establish sensitivity, specificity, and safety of flecainide testing, and to predict a positive test outcome from the baseline ECG. Methods and Results: We performed 160 tests with flecainide in subjects determined to be at risk for BrS. P wave width, PQ duration, QRS width, S wave amplitude and duration in leads II-III, in addition to ST morphology and J point elevation in V1-V3 were measured before and after flecainide administration. Moreover, leads were positioned over the third intercostal space (V1 IC3-V2 IC3). Flecainide tests were considered positive if criteria from the First Consensus Report on BrS were fulfilled. In 64 cases, the test was positive, while 95 were negative (1 test was prematurely interrupted). The sensitivity and specificity, calculated in SCN5A-positive probands and their family members, were 77% and 80%, respectively. Baseline ECGs exhibited significant group differences in P, PQ, and QRS duration, J point elevation (leads V1-V2 and V1 IC3-V2 IC3), and S duration in II, but an attempt to predict the outcome of flecainide testing from these baseline ECG parameters failed. No malignant arrhythmias were observed. Conclusion: Flecainide testing is a valid and safe tool to identify SCN5A-related BrS patients. Baseline ECGs do not predict test outcomes, but point to conduction slowing as a core mechanism in BrS.

Original languageEnglish
Pages (from-to)857-864
Number of pages8
JournalJournal of Cardiovascular Electrophysiology
Volume17
Issue number8
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Flecainide
Brugada Syndrome
Electrocardiography
Cardiac Arrhythmias
Sodium Channel Blockers
Sensitivity and Specificity
Consensus
Safety

Keywords

  • Arrhythmia
  • Brugada syndrome
  • Electrocardiogram
  • Flecainide
  • Genetics
  • Ion channels

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. / Meregalli, Paola G.; Ruijter, Jan M.; Hofman, Nynke; Bezzina, Connie R.; Wilde, Arthur A M; Tan, Hanno L.

In: Journal of Cardiovascular Electrophysiology, Vol. 17, No. 8, 08.2006, p. 857-864.

Research output: Contribution to journalArticle

Meregalli, Paola G. ; Ruijter, Jan M. ; Hofman, Nynke ; Bezzina, Connie R. ; Wilde, Arthur A M ; Tan, Hanno L. / Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. In: Journal of Cardiovascular Electrophysiology. 2006 ; Vol. 17, No. 8. pp. 857-864.
@article{b2bf2bb31e2842da872877e5ae416afe,
title = "Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome",
abstract = "Introduction: Provocation tests with sodium channel blockers are often required to unmask ECG abnormalities in Brugada syndrome (BrS). However, their diagnostic value is only partially established, while life-threatening ventricular arrhythmias during these tests were reported. We aimed to establish sensitivity, specificity, and safety of flecainide testing, and to predict a positive test outcome from the baseline ECG. Methods and Results: We performed 160 tests with flecainide in subjects determined to be at risk for BrS. P wave width, PQ duration, QRS width, S wave amplitude and duration in leads II-III, in addition to ST morphology and J point elevation in V1-V3 were measured before and after flecainide administration. Moreover, leads were positioned over the third intercostal space (V1 IC3-V2 IC3). Flecainide tests were considered positive if criteria from the First Consensus Report on BrS were fulfilled. In 64 cases, the test was positive, while 95 were negative (1 test was prematurely interrupted). The sensitivity and specificity, calculated in SCN5A-positive probands and their family members, were 77{\%} and 80{\%}, respectively. Baseline ECGs exhibited significant group differences in P, PQ, and QRS duration, J point elevation (leads V1-V2 and V1 IC3-V2 IC3), and S duration in II, but an attempt to predict the outcome of flecainide testing from these baseline ECG parameters failed. No malignant arrhythmias were observed. Conclusion: Flecainide testing is a valid and safe tool to identify SCN5A-related BrS patients. Baseline ECGs do not predict test outcomes, but point to conduction slowing as a core mechanism in BrS.",
keywords = "Arrhythmia, Brugada syndrome, Electrocardiogram, Flecainide, Genetics, Ion channels",
author = "Meregalli, {Paola G.} and Ruijter, {Jan M.} and Nynke Hofman and Bezzina, {Connie R.} and Wilde, {Arthur A M} and Tan, {Hanno L.}",
year = "2006",
month = "8",
doi = "10.1111/j.1540-8167.2006.00531.x",
language = "English",
volume = "17",
pages = "857--864",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome

AU - Meregalli, Paola G.

AU - Ruijter, Jan M.

AU - Hofman, Nynke

AU - Bezzina, Connie R.

AU - Wilde, Arthur A M

AU - Tan, Hanno L.

PY - 2006/8

Y1 - 2006/8

N2 - Introduction: Provocation tests with sodium channel blockers are often required to unmask ECG abnormalities in Brugada syndrome (BrS). However, their diagnostic value is only partially established, while life-threatening ventricular arrhythmias during these tests were reported. We aimed to establish sensitivity, specificity, and safety of flecainide testing, and to predict a positive test outcome from the baseline ECG. Methods and Results: We performed 160 tests with flecainide in subjects determined to be at risk for BrS. P wave width, PQ duration, QRS width, S wave amplitude and duration in leads II-III, in addition to ST morphology and J point elevation in V1-V3 were measured before and after flecainide administration. Moreover, leads were positioned over the third intercostal space (V1 IC3-V2 IC3). Flecainide tests were considered positive if criteria from the First Consensus Report on BrS were fulfilled. In 64 cases, the test was positive, while 95 were negative (1 test was prematurely interrupted). The sensitivity and specificity, calculated in SCN5A-positive probands and their family members, were 77% and 80%, respectively. Baseline ECGs exhibited significant group differences in P, PQ, and QRS duration, J point elevation (leads V1-V2 and V1 IC3-V2 IC3), and S duration in II, but an attempt to predict the outcome of flecainide testing from these baseline ECG parameters failed. No malignant arrhythmias were observed. Conclusion: Flecainide testing is a valid and safe tool to identify SCN5A-related BrS patients. Baseline ECGs do not predict test outcomes, but point to conduction slowing as a core mechanism in BrS.

AB - Introduction: Provocation tests with sodium channel blockers are often required to unmask ECG abnormalities in Brugada syndrome (BrS). However, their diagnostic value is only partially established, while life-threatening ventricular arrhythmias during these tests were reported. We aimed to establish sensitivity, specificity, and safety of flecainide testing, and to predict a positive test outcome from the baseline ECG. Methods and Results: We performed 160 tests with flecainide in subjects determined to be at risk for BrS. P wave width, PQ duration, QRS width, S wave amplitude and duration in leads II-III, in addition to ST morphology and J point elevation in V1-V3 were measured before and after flecainide administration. Moreover, leads were positioned over the third intercostal space (V1 IC3-V2 IC3). Flecainide tests were considered positive if criteria from the First Consensus Report on BrS were fulfilled. In 64 cases, the test was positive, while 95 were negative (1 test was prematurely interrupted). The sensitivity and specificity, calculated in SCN5A-positive probands and their family members, were 77% and 80%, respectively. Baseline ECGs exhibited significant group differences in P, PQ, and QRS duration, J point elevation (leads V1-V2 and V1 IC3-V2 IC3), and S duration in II, but an attempt to predict the outcome of flecainide testing from these baseline ECG parameters failed. No malignant arrhythmias were observed. Conclusion: Flecainide testing is a valid and safe tool to identify SCN5A-related BrS patients. Baseline ECGs do not predict test outcomes, but point to conduction slowing as a core mechanism in BrS.

KW - Arrhythmia

KW - Brugada syndrome

KW - Electrocardiogram

KW - Flecainide

KW - Genetics

KW - Ion channels

UR - http://www.scopus.com/inward/record.url?scp=33746061309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746061309&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8167.2006.00531.x

DO - 10.1111/j.1540-8167.2006.00531.x

M3 - Article

C2 - 16764707

AN - SCOPUS:33746061309

VL - 17

SP - 857

EP - 864

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 8

ER -